Refractory CRPS Patients Discontinue Opiates With Cannabinoid

Montreal—An oral cannabinoid was associated with up to 60% reductions in pain in 10 patients with refractory complex regional pain syndrome (CRPS), according to research presented at the 2010 annual World Congress on Pain in Montreal. The study investigators also reported that most of the patients were able to discontinue long-term opioid therapy and reported significant improvements in quality of life.

The findings support the need for more studies that will examine cannabinoid treatment in the CRPS population, said Mark Ware, MBBS, assistant professor in the Departments of Anesthesia and Family Medicine at McGill University in Montreal, Quebec, Canada.

“Given that few more at